Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 7/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.43 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20968680 | 0.90 | NFKB1 (0.43) | TDP1DRD2MAN2B1MEN1GAA | |
| SCHEMBL20228106 | 0.84 | NFKB1 (0.39) | TDP1DRD2CA12CA1CA2 | |
| SCHEMBL19703902 | 0.81 | EPHX1 (0.33) | DRD2 | |
| SCHEMBL17738032 | 0.79 | TDP1 (0.56) | TDP1DRD2MAOAMAOBCA12 | |
| SCHEMBL28508194 | 0.79 | TDP1 (0.56) | TDP1DRD2MAOAMAOBCA12 | |
| SCHEMBL7801592 | 0.79 | TDP1 (0.56) | TDP1DRD2MAOAMAOBCA12 | |
| SCHEMBL19703886 | 0.78 | HTT (0.36) | MEN1GAAKMT2A | |
| SCHEMBL1449045 | 0.78 | TDP1 (0.54) | TDP1DRD2MAOAMAOBCA12 | |
| SCHEMBL22419937 | 0.77 | PLK1 (0.41) | CA12CA1CA2CA9 | |
| SCHEMBL27317330 | 0.77 | TDP1 (0.56) | TDP1DRD2MAOAMAOBMAN2B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556895-B2 | Quaternary amine compounds and antibody-drug conjugates thereof | GENENTECH, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10017577-B2 | Antibodies and immunoconjugates | GENENTECH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170232113-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017577-B2 | Antibodies and immunoconjugates | FCGR3B, CD47, FCGR1A | TDP1 4264/4885DRD2 2925/4885MAOA 3283/4885 |
| US-20170232113-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | H1-5, H1-4, CD47 | TDP1 872/4885DRD2 521/4885MAOA 762/4885 |
| US-10556895-B2 | Quaternary amine compounds and antibody-drug conjugates thereof | H1-5, H1-4, CD47 | TDP1 872/4885DRD2 521/4885MAOA 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.